Opinion
Lorenzo Falchi
Lorenzo Falchi/LinkedIn

Lorenzo Falchi: New Insights on Treatment for Primary Cutaneous DLBCL, Leg Type

Lorenzo Falchi, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared on LinkedIn about a recent paper by Giulio Cassanello et al. published on Blood Cancer Journal:

“In this open-access article we suggest that patients with primary cutaneous DLBCL, leg type may benefit from combined chemotherapy and radiation therapy.

Their CNS relapse risk is also higher and we suggest considering CNS prophylaxis when feasible.

Thank you Giulio Cassanello, Matthew Matasar, and my colleagues at MSKCC for a wonderful collaboration!”

Title: Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era

Authors: Giulio Cassanello, Esther Drill, Annie Qiu, Mark D. Ewalt, Paul Hamlin, Steven M. Horwitz, Erel Joffe, Anita Kumar, Alison J. Moskowitz, Ariela Noy, Colette Owens, Maria Lia Palomba, Andrew D. Zelenetz, Ahmet Dogan, Klaus J. Busam, Joachim Yahalom, Gilles Salles, Matthew J. Matasar & Lorenzo Falchi

Read the full article.

Lorenzo Falchi

More posts featuring Lorenzo Falchi.

Ahmet Dogan Alison J. Moskowitz Andrew D. Zelenetz Anita Kumar Annie Qiu Ariela Noy cancer chemotherapy Colette Owens DLBCL Erel Joffe Esther Drill Gilles Salles Giulio Cassanello Joachim Yahalom Klaus J. Busam Leg Type Lorenzo Falchi Maria Lia Palomba Mark D. Ewalt Matthew J. Matasar Matthew Matasar MSKCC OncoDaily Oncology Paul Hamlin radiation therapy Steven M Horwitz.